Canagliflozin is an oral c-glucoside sodium-dependent glucose type 2 co-transporter (SGLT2) inhibitor originally developed by biopharma, which can reduce glucose by blocking the reabsorption of Chemicalbook glucose from the proximal flex tubule
*The following content is generated by AI and is for reference only.
Overview
Canagliflozin hemi-hydrate is the hydrated crystalline form of a selective SGLT2 inhibitor. Produced via multi-step organic synthesis with precise hydration control, its molecular formula is C18H21CaNaO9·0.5H2O (CAS: 1074659-61-6).
Application
- Pharmaceutical manufacturing for Type 2 diabetes management.
- Active Pharmaceutical Ingredient (API) supply for oral tablet formulations.
- Research applications in metabolic disorder studies.
Precautions
Store in cool, dry conditions below 25°C to prevent dehydration or degradation. Handle with standard PPE; avoid inhalation of dust and direct skin contact during processing.